Fasting serum glucose

1 paper1 finding

Human trial1

Interventions

1

Tirzepatide

downin humans1

1 study

Tirzepatide decreases fasting serum glucose in humans.
“all tirzepatide doses were superior to placebo for changes from baseline in HbA1c, fasting serum glucose, bodyweight”
Human trialtype 2 diabetes5 mg, 10 mg, or 15 mg once a week40 weeks
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Lancet (London, England)27 Jun 2021

More on Tirzepatide

Latest

4 in 12 months

Georgian Medical News5 Oct

ASSOCIATION BETWEEN INFLAMMATORY MARKERS, LIVER ENZYMES, LIPID PROFILE, AND VITAMIN D STATUS IN ADULTS WITH OBESITY: A CROSS-SECTIONAL STUDY

Cross-sectional study of 68 peopleObesity

Women's Health1 Oct

Associations of pre-pregnancy weight, gestational weight gain, and postpartum weight retention with metabolic health: Findings from the MISC cohort study

Cohort study of 256 peoplePopulations

Nutrition, Metabolism, and Cardiovascular Diseases18 Sep

Chronic coffee consumption and diabetogenic risk: data from the PAMELA study

Cohort study of 1,158 peoplePopulations

Journal of the Endocrine Society27 Aug

Glycemia-based predictors of T2D development in adults with obesity and prediabetes: SURMOUNT-1 post hoc analysis

Randomised trial in peoplePrediabetes

ENDO 2025 Abstract23 Oct

MON-242 Effects of Liraglutide on Body Composition Distribution in Adolescents with Refractory Obesity Post-Vertical Sleeve Gastrectomy

Non-randomised trial in 31 peopleLiraglutide

Lancet27 Jun

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Randomised trial in 478 peopleGLP-1 receptor agonists